117997-63-4

Upstream product

• 58881-45-1 Indole-2-carbonyl chloride 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 123540-75-0 (R)-4-tert-Butoxycarbonylamino-4-dicyclohexylcarbamoyl-butyric acid benzyl ester 
• 35793-73-8 N-(tert-butyloxycarbonyl)-γ-benzyl-D-glutamic acid 
• 117997-62-3 (R)-4-Dicyclohexylcarbamoyl-4-[(1H-indole-2-carbonyl)-amino]-butyric acid benzyl ester 

Relevant academic research and scientific papers

Novel glutamic acid derived cholecystokinin receptor ligands

Novel aryl amide analogues of glutamic acid dialkylamide have been synthesized to test for a possible structural analogy between glutamic acid and benzodiazepine CCK antagonists such as compounds 2 and 24 (lorglumide and MK-329, respectively). In support of the structural model, certain of these hybrid compounds are more potent in pancreas CCK radioligand binding assays than corresponding lorglumide-type reference compounds. Modifications previously found in the benzodiazepine antagonists to result in brain CCK/gastrin receptor selectivity were also incorporated to produce an aryl urea series of glutamic acid analogues. None of these compounds were brain CCK/gastrin selective; however, one was potent and selective in the pancreas binding assay. The model appears to be most useful in the design of selective ligands for the pancreas type CCK receptor.

Amino acid analogs

Analogs of glutamic acid and related amino acids and pharmaceutically-acceptable salts thereof which antagonize the function of cholecystokinins and gastrin disease states in animals and compositions for and methods of preventing or treating disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.